LBRX
LB PHARMACEUTICALS INC
NASDAQ · Healthcare · Biotechnology · US
$40.15
+0.80%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$1.62
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$1.71
- EPS estimate
- -$0.80
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 1
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -27.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $60
- PT range
- $35 – $80
- Analysts
- 6
4 Buy2 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.80 | -$1.71 | Miss -112.78% | — |
| May 12, 2026 | -$0.75 | -$0.67 | Beat 10.67% | — |
| Mar 26, 2026 | -$0.45 | -$0.45 | In line | — |
| Nov 6, 2025 | -$0.57 | -$0.61 | Miss -7.02% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026